| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 03/09/2006 | US20060051349 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 03/09/2006 | DE19681616B4 Prozeß zur Gewinnung von Oestrogenen aus Stutenharn Process for the production of estrogens from Stutenharn |
| 03/09/2006 | CA2578852A1 Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency |
| 03/09/2006 | CA2578194A1 Androgen modulators |
| 03/08/2006 | EP1632470A2 Calcium receptor active molecules |
| 03/08/2006 | EP1423407B1 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds |
| 03/08/2006 | EP1406628B1 Tetrahydroquinoline derivatives |
| 03/08/2006 | EP1294389B1 Therapeutical use of sophora flavescens or sophora subprostrata extracts |
| 03/08/2006 | EP1274407B1 Uses of ppar-gamma agonists in neutrophil-induced diseases |
| 03/08/2006 | EP1237565B1 Betaglycan as an inhibin receptor and uses thereof |
| 03/08/2006 | EP1003774B1 GnRH ANTAGONISTS BEING MODIFIED IN POSITIONS 5 AND 6 |
| 03/08/2006 | EP0889727B1 Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy |
| 03/08/2006 | EP0870039B1 Recombinant fusion proteins to growth hormone and serum albumin |
| 03/08/2006 | EP0733109B1 Bmp-12, bmp-13 and tendon-inducing compositions thereof |
| 03/08/2006 | CN1745080A 1,3-dihydroimidazole fused-ring compound |
| 03/08/2006 | CN1744930A 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 03/08/2006 | CN1744910A Drugs containing galectin 9 |
| 03/08/2006 | CN1244578C Substituted benzofuran-2-carboxamides derivatives |
| 03/08/2006 | CN1244576C Chemical compounds |
| 03/07/2006 | US7008948 Fused pyrimidyl pyrazole compounds useful as protein kinase inhibitors |
| 03/07/2006 | US7008927 Pralmorelin-containing nasal drop preparations |
| 03/07/2006 | US7008640 Mixture of drug, aminoacrylate polymer and acid |
| 03/02/2006 | WO2006023158A2 Mineralocorticoid receptor modulator compounds and methods, and pharmaceutical compositions containing these compounds |
| 03/02/2006 | WO2006022420A1 Preventives/remedies for stress urinary incontinence and method of screening the same |
| 03/02/2006 | WO2006022301A1 Liquid preparation of physiologically active peptide |
| 03/02/2006 | WO2006021418A1 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives as crth2 antagonists |
| 03/02/2006 | WO2003031464A3 Remodeling and glycoconjugation of peptides |
| 03/02/2006 | CA2577748A1 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives as crth2 antagonists |
| 03/02/2006 | CA2576473A1 Liquid preparation of physiologically active peptide |
| 03/02/2006 | CA2573314A1 Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof |
| 03/02/2006 | CA2573310A1 Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof |
| 03/01/2006 | EP1630162A1 2-aminoquinoline derivative |
| 03/01/2006 | EP1629845A2 Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders |
| 03/01/2006 | EP1629832A1 A pharmaceutical formulation comprising human growth hormone, an amino acid and a non-ionic detergent |
| 03/01/2006 | EP1628979A1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors |
| 03/01/2006 | EP1628669A1 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| 03/01/2006 | EP1409500B1 Alkylated inositolglycans and their uses |
| 03/01/2006 | EP1319007B1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 03/01/2006 | EP1105409B1 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| 03/01/2006 | CN1741819A Sustained release composition for oral administration of drugs |
| 03/01/2006 | CN1740182A Novel bisamidate phosphonate prodrugs |
| 03/01/2006 | CN1739795A Prepn process of slow release parathyroid hormone microballoon |
| 03/01/2006 | CN1739733A Chinese medicine prepn for treating hyperthyroidosis and its prepn process |
| 03/01/2006 | CN1739527A The use of non-oral androgenic steroids in the manufacture of medicine for improving elevated sex hormone binding globulin levels |
| 03/01/2006 | CN1243751C Piperidine compounds as anti-allergic medicine |
| 03/01/2006 | CN1243550C Pharmaceutical compositions and uses for androst-5-ene-3beta, 17 beta-diol and use thereof |
| 02/28/2006 | US7005538 N-[3,5-Dibromo-4-(3-bromobenzyloxy)benzoyl]benzenesulphonamide for example; use to treat cardiac arrhythmias, thyrotoxicosis and subclinical hyperthyroidism |
| 02/28/2006 | CA2331877C Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them |
| 02/23/2006 | WO2006019169A1 3-epivitamin d3 derivative and therapeutic agent containing the same |
| 02/23/2006 | WO2006018850A2 Compositions for treating amyloid associated diseases |
| 02/23/2006 | WO2006018723A2 Androgen modulators |
| 02/23/2006 | US20060040963 Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 02/23/2006 | US20060040933 Antiinflammatory agents |
| 02/23/2006 | US20060040876 Modulation of peroxisome proliferator-activated receptors |
| 02/23/2006 | US20060040266 Diagnostics and therapeutics for diseases associated with neuromedin u2 receptor (nmu2) |
| 02/23/2006 | US20060039903 Immunomodulation and effect on cell processes relating to serotonin family receptors |
| 02/23/2006 | DE202005020404U1 Mixture for reduction of troubles or nourishment supplement in menopause, comprises phytoestrogen active agent, antioxidant and carrier agents |
| 02/23/2006 | DE102004036047A1 Physiologisch aktive Zusammensetzung Physiologically active composition |
| 02/23/2006 | CA2577448A1 Androgen modulators |
| 02/22/2006 | EP1627870A1 Cyanofluoropyrrolidine derivative |
| 02/22/2006 | EP1627642A2 Zinc free insulin crystals for use in pulmonary compositions |
| 02/22/2006 | EP1406622B1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 02/22/2006 | EP1224187B1 Certain alkylene diamine-substituted heterocycles |
| 02/22/2006 | EP1051193B1 Anhydrous topical skin preparation comprising ketoconazole |
| 02/22/2006 | CN1738800A 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 02/22/2006 | CN1738788A Substituted phenyl naphthalenes as estrogenic agents |
| 02/22/2006 | CN1738617A Pharmaceutical compositions for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases |
| 02/22/2006 | CN1738599A Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| 02/22/2006 | CN1736985A Growth hormone secretagogues |
| 02/22/2006 | CN1736981A Selective androgen receptor modulators and methods of use thereof |
| 02/22/2006 | CN1736461A Composite vegetable drug for treating type II diabetes and increasing insulin sensitivity, extracts and extraction method |
| 02/22/2006 | CN1736383A Compound lycopene formulation for women and preparation process thererof |
| 02/22/2006 | CN1736371A Selective androgen receptor modulators and methods of use thereof |
| 02/22/2006 | CN1243000C Tocopherols, tocotrienols, other chroman and side chain dervative and uses thereof |
| 02/22/2006 | CN1242991C Aporphine esters and their use in therapy |
| 02/21/2006 | US7001910 substituted pyrimidinyl-amino-ethoxy benzyl-thiazolidine-diones; hypoglycemic agents |
| 02/21/2006 | CA2395196C Cyclic amp-specific phosphodiesterase inhibitors |
| 02/21/2006 | CA2250258C Novel tetralone or benzopyranone derivatives and process for producing the same |
| 02/16/2006 | WO2003025129A3 Neurotransmission-associated proteins |
| 02/16/2006 | US20060036089 33 human secreted proteins |
| 02/16/2006 | US20060035899 Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein |
| 02/16/2006 | US20060035315 Transporters and ion channels |
| 02/16/2006 | US20060034818 Placental alkaline phosphatase to control diabetes |
| 02/16/2006 | DE102004035322A1 Selektive Hemmstoffe humaner Corticoidsynthasen Selective inhibitors of human Corticoidsynthasen |
| 02/16/2006 | CA2575486A1 Crystalline polymorph of pipindoxifene hydrochloride monohydrate |
| 02/16/2006 | CA2572325A1 Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide |
| 02/15/2006 | EP1625847A1 Pharmaceutical composition comprising a tetrahydrotriazolo[4,3-a]pyrazine |
| 02/15/2006 | EP1624898A1 Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues |
| 02/15/2006 | EP1341533B1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 02/15/2006 | CN1733807A Fusion protein possessing growth facilitation action and its coding gene and uses |
| 02/14/2006 | US6998503 crystallized as an anhydrous, stoichiometric 1.5 HCl salt; inhibiting or modulating nitric oxide synthesis |
| 02/14/2006 | CA2450740C Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 02/14/2006 | CA2363145C Oxamic acids and derivatives as thyroid receptor ligands |
| 02/09/2006 | WO2002088316A3 G-protein coupled receptors |
| 02/09/2006 | US20060030561 2-Benzyl-2-hydroxy-4-methyl-4-phenylpentanoic acid (1-oxo-1,3-dihydroisobenzofuran-5-yl)amide for example; treating type II diabetes, obesity, hypertension, arteriosclerosis, or glaucoma |
| 02/09/2006 | US20060030557 Substituted pyridines having antiangiogenic activity |
| 02/09/2006 | CA2575612A1 Methods of treating ccr2 mediated diseases or disorders |
| 02/08/2006 | EP1623994A2 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| 02/08/2006 | EP1623984A1 Polymorphic form I of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt |
| 02/08/2006 | EP1623711A1 External patch containing estrogen and/or progestogen |